샘플 요청 목록

 카트 문의
시장보고서
상품코드
1427064

전신피부경화증 치료제 시장 : 세계 산업 분석, 규모, 점유율, 성장, 동향 및 예측(2031년) - 표적 장기별, 치료 유형별, 투여 경로별, 유통 채널별, 지역별

Systemic Scleroderma Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region:
발행일: | 리서치사: Fairfield Market Research | 페이지 정보: 영문 380 Pages | 배송안내 : 2-5일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계 전신 피부경화증 치료제 시장 규모는 예측 기간인 2024년부터 2031년까지 큰 폭으로 성장할 것으로 예상됩니다. 현재 8억 5,000만 달러 규모인 이 시장은 2031년 말까지 16억 5,000만 달러로 급성장할 것으로 예상됩니다. 이러한 성장 궤적은 전신피부경화증에 대한 효과적인 치료 옵션에 대한 수요가 전 세계적으로 증가하고 있음을 입증합니다.

전신피부경화증 치료 시장을 촉진하는 주요 요인 중 하나는 예방적 건강 관리에 대한 인식이 높아지고 있다는 점입니다. 전신피부경화증과 같은 자가면역질환에 초점을 맞춘 교육 프로그램 및 워크숍은 질환 적응증에 대한 반응성을 향상시키는 데 기여하고 있습니다. 또한, 생물학적 제제 및 저분자 병용요법과 같은 혁신적인 치료법의 개발은 이 분야의 제약사들에게 큰 기회를 제공합니다.

Cannabidiol(CBD) 유래 경구용 제제인 에메랄드 헬스 파마슈티컬스(Emerald Health Pharmaceuticals)의 EHP-101은 현재 전신피부경화증에 대한 임상 2상 시험이 진행 중이며, 이는 이 분야의 기업이 추구하는 혁신적 접근법의 한 예일 뿐입니다.

유망한 전망에도 불구하고 전신강직성피부병 치료에는 여전히 과제가 남아있습니다. 치료법을 평가할 수 있는 표준화된 프레임워크의 부재와 질병 조절 항우울제의 효과가 입증되지 않은 점이 수요 증가를 저해하고 있습니다. 임상시험은 이 질환의 낮은 유병률, 다양한 임상 증상, 변화무쌍한 경과로 인해 일관성 없는 결과를 초래하는 장애물에 직면해 있습니다.

본 보고서는 세계 전신피부경화증 치료제 시장에 대해 조사했으며, 시장 개요와 함께 표적 장기별, 치료 유형별, 투여 경로별, 유통 채널별, 지역별 동향, 시장 진출기업의 경쟁 동향 등을 조사하여 전해드립니다.

목차

제1장 주요 요약

제2장 시장 개요

  • 시장 정의와 세분화
  • 시장 역학
  • 밸류체인 분석
  • Porter의 Five Forces 분석
  • COVID-19의 영향 분석
  • 우크라이나와 러시아 분쟁의 영향
  • 경제 개요
  • PESTLE 분석

제3장 세계의 전신피부경화증 치료 시장 전망, 2018년-2031년

  • 세계의 전신피부경화증 치료 시장 전망, 표적 장기별, 금액(100만 달러), 2018년-2031년
  • 세계의 전신피부경화증 치료 시장 전망, 치료 유형별, 금액(100만 달러), 2018년-2031년
  • 세계의 전신피부경화증 치료 시장 전망, 투여 경로별, 금액(100만 달러), 2018년-2031년
  • 세계의 전신피부경화증 치료 시장 전망, 유통 채널별, 금액(100만 달러), 2018년-2031년
  • 세계의 전신피부경화증 치료 시장 전망, 지역별, 금액(100만 달러), 2018년-2031년

제4장 북미의 전신피부경화증 치료 시장 전망, 2018년-2031년

제5장 유럽의 전신피부경화증 치료 시장 전망, 2018년-2031년

제6장 아시아태평양의 전신피부경화증 치료 시장 전망, 2018년-2031년

제7장 라틴아메리카의 전신피부경화증 치료 시장 전망, 2018년-2031년

제8장 중동 및 아프리카의 전신피부경화증 치료 시장 전망, 2018년-2031년

제9장 경쟁 구도

  • 표적 장기와 투여 경로 히트맵
  • 제조업체와 적응증 히트맵
  • 기업의 시장 점유율 분석, 2023년
  • 경쟁 대시보드
  • 기업 개요
    • Pfizer Inc.
    • Novartis AG
    • GlaxoSmithKline plc.
    • Sanofi SA
    • Lupin Ltd
    • Cipla Ltd
    • Johnson & Johnson Services Inc.
    • Bayer Healthcare LLC
    • F. Hoffmann-La Roche Ltd
    • Amgen Inc
    • Zydus Lifesciences Ltd
    • Casper Pharma
    • Boehringer Ingelheim Pharmaceuticals, Inc.
    • Organon LLC
    • Accord Healthcare Inc.

제10장 부록

LSH 24.02.27

Comprehensive Industry Analysis Reveals Robust Growth Opportunities

The global systemic scleroderma treatment market is witnessing substantial growth over the forecast period 2024-2031. According to Fairfield Market Research, the market is currently valued at US$ 850 million, and is anticipated to surge to a valuation of US$ 1650 million by the end of 2031. This growth trajectory underscores the increasing demand for effective treatment options for systemic scleroderma worldwide.

Increasing Awareness and Strong Product Pipeline Driving Market Growth

One of the key drivers propelling the systemic scleroderma treatment market is the rising awareness about preventive healthcare initiatives. Awareness programs and workshops focusing on autoimmune disorders like systemic scleroderma are contributing to greater responsiveness towards disease indications. Additionally, the development of innovative therapies such as biologics and small molecule combination therapies is opening up significant opportunities for drug manufacturers in this space.

Emerald Health Pharmaceuticals' EHP-101, an oral formulation derived from cannabidiol (CBD), is currently in phase II trials for systemic scleroderma, representing just one example of the innovative approaches being pursued by companies in the field.

Challenges Hindering Market Growth

Despite the promising outlook, challenges remain in the systemic scleroderma treatment landscape. A lack of standardized frameworks for assessing treatments and the absence of proven efficacy in disease-modifying anti-drugs are impeding demand growth. Clinical trials face hurdles due to the disease's low prevalence, diverse clinical manifestations, and fluctuating course, leading to inconsistent outcomes.

Country-wise Insights Highlight Regional Dynamics

  • United States: With the highest prevalence of systemic scleroderma, the U.S. accounts for a significant share of the North American market. Increasing focus on the treatment of rare diseases and USFDA approvals for systemic scleroderma drugs are driving market growth in this region.
  • Germany: Favorable guidelines for systemic scleroderma treatment in Germany are facilitating steady market growth, with researchers leveraging diagnostic scores and clinical features to advance therapy approaches.
  • Japan: Ongoing R&D efforts in Japan, highlighted by companies like Kyowa Kirin and J&J, are propelling the country's emergence as a prominent market for systemic scleroderma treatment.
  • Australia: High prevalence rates and increasing mortality underscore the growing demand for systemic scleroderma treatments in Australia, driven by biomedical research discoveries and the introduction of new medical products.

Category-wise Insights Drive Market Understanding

  • Drug Therapy Segment: Off-label use of drugs approved for symptomatic indications is a key driver of market growth, with drug therapy expected to dominate the systemic scleroderma treatment market.
  • Route of Administration: Injectable drugs are preferred for their safety and efficacy, comprising the majority of systemic scleroderma treatment options.
  • Sales Channels: Hospital pharmacies dominate sales due to the need for skilled medical administration, with intravenous drug administration being common for systemic scleroderma treatments.

Impact of COVID-19

While the COVID-19 pandemic disrupted healthcare supply chains, studies have shown a neutral impact on the systemic scleroderma treatment market. However, patients with systemic scleroderma-related interstitial lung involvement faced higher risks of severe COVID-19, highlighting the importance of continued research and treatment development.

Competitive Analysis

Key players in the systemic scleroderma treatment market are forging strategic partnerships and acquisitions to expand their product portfolios and drive innovation. Recent partnerships include Boehringer Ingelheim with PetMedix and Lupin ltd with Shenzhen Foncoo Pharmaceutical Co. Ltd, underscoring the industry's commitment to advancing treatment options.

As the market continues to evolve, collaborations and investments in R&D will play a crucial role in addressing the unmet needs of systemic scleroderma patients worldwide.

Key Companies Profiled:

  • Pfizer Inc.
  • Novartis AG
  • GlaxoSmithKline plc.
  • Sanofi SA
  • Lupin Ltd
  • Cipla Ltd
  • Teva Pharmaceuticals
  • Johnson & Johnson Services Inc.
  • Bayer Healthcare LLC
  • F. Hoffmann-La Roche Ltd
  • Amgen Inc
  • Zydus Lifesciences Ltd
  • Casper Pharma
  • Boehringer Ingelheim Pharmaceuticals, Inc.
  • Organon LLC
  • Accord Healthcare Inc.

Key Segments Covered in Systemic Scleroderma Treatment Industry Survey

Systemic Scleroderma Treatment Market by Target Organ:

  • Skin Fibrosis
  • Musculoskeletal
  • Digital Ulcers
  • Pulmonary Arterial Hypertension
  • Gastrointestinal
  • Pulmonary Fibrosis
  • Scleroderma Renal Crisis

Systemic Scleroderma Treatment Market by Treatment Type:

  • Drug Therapy
    • Corticosteroids
    • Immunosuppressants
    • Nonsteroidal Anti-Inflammatory Drugs
    • Calcium Channel Blockers
    • Proton Pump Inhibitors
    • TNF Inhibitors
    • Endothelin Receptor Antagonists
    • Phosphodiesterase Type 5 Inhibitors
    • Angiotensin-Converting Enzyme
  • Hematopoietic Stem Cell Transplantation (HSCT)

Systemic Scleroderma Treatment Market by Route of Administration:

  • Injectable Systemic Scleroderma Drugs
  • Oral Systemic Scleroderma Drugs
  • Topical Systemic Scleroderma Drugs

Systemic Scleroderma Treatment Market by Distribution Channel:

  • Hospital Pharmacies
  • Speciality Clinics
  • Retail Pharmacies
  • Online Pharmacies

Systemic Scleroderma Treatment Market by Region:

  • North America Systemic Scleroderma Treatment Market
  • Latin America Systemic Scleroderma Treatment Market
  • Europe Systemic Scleroderma Treatment Market
  • South Asia Systemic Scleroderma Treatment Market
  • East Asia Systemic Scleroderma Treatment Market
  • Oceania Systemic Scleroderma Treatment Market
  • The Middle East & Africa Systemic Scleroderma Treatment Market

Table of Contents

1. Executive Summary

  • 1.1. Global Systemic Scleroderma Treatment Market Snapshot
  • 1.2. Future Projections
  • 1.3. Key Market Trends
  • 1.4. Regional Snapshot, by Value, 2023
  • 1.5. Analyst Recommendations

2. Market Overview

  • 2.1. Market Definitions and Segmentations
  • 2.2. Market Dynamics
    • 2.2.1. Drivers
    • 2.2.2. Restraints
    • 2.2.3. Market Opportunities
  • 2.3. Value Chain Analysis
  • 2.4. Porter's Five Forces Analysis
  • 2.5. COVID-19 Impact Analysis
    • 2.5.1. Supply
    • 2.5.2. Demand
  • 2.6. Impact of Ukraine-Russia Conflict
  • 2.7. Economic Overview
    • 2.7.1. World Economic Projections
  • 2.8. PESTLE Analysis

3. Global Systemic Scleroderma Treatment Market Outlook, 2018 - 2031

  • 3.1. Global Systemic Scleroderma Treatment Market Outlook, by Target Organ, Value (US$ Mn), 2018 - 2031
    • 3.1.1. Key Highlights
      • 3.1.1.1. Skin Fibrosis
      • 3.1.1.2. Musculoskeletal
      • 3.1.1.3. Digital Ulcers
      • 3.1.1.4. Pulmonary Arterial Hypertension
      • 3.1.1.5. Gastrointestinal
      • 3.1.1.6. Pulmonary Fibrosis
      • 3.1.1.7. Scleroderma Renal Crisis
  • 3.2. Global Systemic Scleroderma Treatment Market Outlook, by Treatment Type, Value (US$ Mn), 2018 - 2031
    • 3.2.1. Key Highlights
      • 3.2.1.1. Drug Therapy
        • 3.2.1.1.1. Corticosteroids
        • 3.2.1.1.2. Immunosuppressants
        • 3.2.1.1.3. Nonsteroidal Anti-Inflammatory Drugs
        • 3.2.1.1.4. Calcium Channel Blockers
        • 3.2.1.1.5. Proton Pump Inhibitors
        • 3.2.1.1.6. TNF Inhibitors
        • 3.2.1.1.7. Endothelin Receptor Antagonists
        • 3.2.1.1.8. Phosphodiesterase Type 5 Inhibitors
        • 3.2.1.1.9. Angiotensin-Converting Enzyme
      • 3.2.1.2. Hematopoietic Stem Cell Transplantation (HSCT)
  • 3.3. Global Systemic Scleroderma Treatment Market Outlook, by Route of Administration, Value (US$ Mn), 2018 - 2031
    • 3.3.1. Key Highlights
      • 3.3.1.1. Injectable Systemic Scleroderma Drugs
      • 3.3.1.2. Oral Systemic Scleroderma Drugs
      • 3.3.1.3. Topical Systemic Scleroderma Drugs
  • 3.4. Global Systemic Scleroderma Treatment Market Outlook, by Distribution Channel, Value (US$ Mn), 2018 - 2031
    • 3.4.1. Key Highlights
      • 3.4.1.1. Hospital Pharmacies
      • 3.4.1.2. Speciality Clinics
      • 3.4.1.3. Retail Pharmacies
      • 3.4.1.4. Online Pharmacies
  • 3.5. Global Systemic Scleroderma Treatment Market Outlook, by Region, Value (US$ Mn), 2018 - 2031
    • 3.5.1. Key Highlights
      • 3.5.1.1. North America
      • 3.5.1.2. Europe
      • 3.5.1.3. Asia Pacific
      • 3.5.1.4. Latin America
      • 3.5.1.5. Middle East & Africa

4. North America Systemic Scleroderma Treatment Market Outlook, 2018 - 2031

  • 4.1. North America Systemic Scleroderma Treatment Market Outlook, by Target Organ, Value (US$ Mn), 2018 - 2031
    • 4.1.1. Key Highlights
      • 4.1.1.1. Skin Fibrosis
      • 4.1.1.2. Musculoskeletal
      • 4.1.1.3. Digital Ulcers
      • 4.1.1.4. Pulmonary Arterial Hypertension
      • 4.1.1.5. Gastrointestinal
      • 4.1.1.6. Pulmonary Fibrosis
      • 4.1.1.7. Scleroderma Renal Crisis
  • 4.2. North America Systemic Scleroderma Treatment Market Outlook, by Treatment Type, Value (US$ Mn), 2018 - 2031
    • 4.2.1. Key Highlights
      • 4.2.1.1. Drug Therapy
        • 4.2.1.1.1. Corticosteroids
        • 4.2.1.1.2. Immunosuppressants
        • 4.2.1.1.3. Nonsteroidal Anti-Inflammatory Drugs
        • 4.2.1.1.4. Calcium Channel Blockers
        • 4.2.1.1.5. Proton Pump Inhibitors
        • 4.2.1.1.6. TNF Inhibitors
        • 4.2.1.1.7. Endothelin Receptor Antagonists
        • 4.2.1.1.8. Phosphodiesterase Type 5 Inhibitors
        • 4.2.1.1.9. Angiotensin-Converting Enzyme
      • 4.2.1.2. Hematopoietic Stem Cell Transplantation (HSCT)
  • 4.3. North America Systemic Scleroderma Treatment Market Outlook, by Route of Administration, Value (US$ Mn), 2018 - 2031
    • 4.3.1. Key Highlights
      • 4.3.1.1. Injectable Systemic Scleroderma Drugs
      • 4.3.1.2. Oral Systemic Scleroderma Drugs
      • 4.3.1.3. Topical Systemic Scleroderma Drugs
  • 4.4. North America Systemic Scleroderma Treatment Market Outlook, by Distribution Channel, Value (US$ Mn), 2018 - 2031
    • 4.4.1. Key Highlights
      • 4.4.1.1. Hospital Pharmacies
      • 4.4.1.2. Speciality Clinics
      • 4.4.1.3. Retail Pharmacies
      • 4.4.1.4. Online Pharmacies
    • 4.4.2. BPS Analysis/Market Attractiveness Analysis
  • 4.5. North America Systemic Scleroderma Treatment Market Outlook, by Country, Value (US$ Mn), 2018 - 2031
    • 4.5.1. Key Highlights
      • 4.5.1.1. U.S. Systemic Scleroderma Treatment Market by Target Organ, Value (US$ Mn), 2018 - 2031
      • 4.5.1.2. U.S. Systemic Scleroderma Treatment Market by Treatment Type, Value (US$ Mn), 2018 - 2031
      • 4.5.1.3. U.S. Systemic Scleroderma Treatment Market by Route of Administration, Value (US$ Mn), 2018 - 2031
      • 4.5.1.4. U.S. Systemic Scleroderma Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
      • 4.5.1.5. Canada Systemic Scleroderma Treatment Market by Target Organ, Value (US$ Mn), 2018 - 2031
      • 4.5.1.6. Canada Systemic Scleroderma Treatment Market by Treatment Type, Value (US$ Mn), 2018 - 2031
      • 4.5.1.7. Canada Systemic Scleroderma Treatment Market by Route of Administration, Value (US$ Mn), 2018 - 2031
      • 4.5.1.8. Canada Systemic Scleroderma Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
    • 4.5.2. BPS Analysis/Market Attractiveness Analysis

5. Europe Systemic Scleroderma Treatment Market Outlook, 2018 - 2031

  • 5.1. Europe Systemic Scleroderma Treatment Market Outlook, by Target Organ, Value (US$ Mn), 2018 - 2031
    • 5.1.1. Key Highlights
      • 5.1.1.1. Skin Fibrosis
      • 5.1.1.2. Musculoskeletal
      • 5.1.1.3. Digital Ulcers
      • 5.1.1.4. Pulmonary Arterial Hypertension
      • 5.1.1.5. Gastrointestinal
      • 5.1.1.6. Pulmonary Fibrosis
      • 5.1.1.7. Scleroderma Renal Crisis
  • 5.2. Europe Systemic Scleroderma Treatment Market Outlook, by Treatment Type, Value (US$ Mn), 2018 - 2031
    • 5.2.1. Key Highlights
      • 5.2.1.1. Drug Therapy
        • 5.2.1.1.1. Corticosteroids
        • 5.2.1.1.2. Immunosuppressants
        • 5.2.1.1.3. Nonsteroidal Anti-Inflammatory Drugs
        • 5.2.1.1.4. Calcium Channel Blockers
        • 5.2.1.1.5. Proton Pump Inhibitors
        • 5.2.1.1.6. TNF Inhibitors
        • 5.2.1.1.7. Endothelin Receptor Antagonists
        • 5.2.1.1.8. Phosphodiesterase Type 5 Inhibitors
        • 5.2.1.1.9. Angiotensin-Converting Enzyme
      • 5.2.1.2. Hematopoietic Stem Cell Transplantation (HSCT)
  • 5.3. Europe Systemic Scleroderma Treatment Market Outlook, by Route of Administration, Value (US$ Mn), 2018 - 2031
    • 5.3.1. Key Highlights
      • 5.3.1.1. Injectable Systemic Scleroderma Drugs
      • 5.3.1.2. Oral Systemic Scleroderma Drugs
      • 5.3.1.3. Topical Systemic Scleroderma Drugs
  • 5.4. Europe Systemic Scleroderma Treatment Market Outlook, by Distribution Channel, Value (US$ Mn), 2018 - 2031
    • 5.4.1. Key Highlights
      • 5.4.1.1. Hospital Pharmacies
      • 5.4.1.2. Speciality Clinics
      • 5.4.1.3. Retail Pharmacies
      • 5.4.1.4. Online Pharmacies
    • 5.4.2. BPS Analysis/Market Attractiveness Analysis
  • 5.5. Europe Systemic Scleroderma Treatment Market Outlook, by Country, Value (US$ Mn), 2018 - 2031
    • 5.5.1. Key Highlights
      • 5.5.1.1. Germany Systemic Scleroderma Treatment Market by Target Organ, Value (US$ Mn), 2018 - 2031
      • 5.5.1.2. Germany Systemic Scleroderma Treatment Market by Treatment Type, Value (US$ Mn), 2018 - 2031
      • 5.5.1.3. Germany Systemic Scleroderma Treatment Market by Route of Administration, Value (US$ Mn), 2018 - 2031
      • 5.5.1.4. Germany Systemic Scleroderma Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
      • 5.5.1.5. U.K. Systemic Scleroderma Treatment Market by Target Organ, Value (US$ Mn), 2018 - 2031
      • 5.5.1.6. U.K. Systemic Scleroderma Treatment Market by Treatment Type, Value (US$ Mn), 2018 - 2031
      • 5.5.1.7. U.K. Systemic Scleroderma Treatment Market by Route of Administration, Value (US$ Mn), 2018 - 2031
      • 5.5.1.8. U.K. Systemic Scleroderma Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
      • 5.5.1.9. France Systemic Scleroderma Treatment Market by Target Organ, Value (US$ Mn), 2018 - 2031
      • 5.5.1.10. France Systemic Scleroderma Treatment Market by Treatment Type, Value (US$ Mn), 2018 - 2031
      • 5.5.1.11. France Systemic Scleroderma Treatment Market by Route of Administration, Value (US$ Mn), 2018 - 2031
      • 5.5.1.12. France Systemic Scleroderma Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
      • 5.5.1.13. Italy Systemic Scleroderma Treatment Market by Target Organ, Value (US$ Mn), 2018 - 2031
      • 5.5.1.14. Italy Systemic Scleroderma Treatment Market by Treatment Type, Value (US$ Mn), 2018 - 2031
      • 5.5.1.15. Italy Systemic Scleroderma Treatment Market by Route of Administration, Value (US$ Mn), 2018 - 2031
      • 5.5.1.16. Italy Systemic Scleroderma Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
      • 5.5.1.17. Turkey Systemic Scleroderma Treatment Market by Target Organ, Value (US$ Mn), 2018 - 2031
      • 5.5.1.18. Turkey Systemic Scleroderma Treatment Market by Treatment Type, Value (US$ Mn), 2018 - 2031
      • 5.5.1.19. Turkey Systemic Scleroderma Treatment Market by Route of Administration, Value (US$ Mn), 2018 - 2031
      • 5.5.1.20. Turkey Systemic Scleroderma Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
      • 5.5.1.21. Russia Systemic Scleroderma Treatment Market by Target Organ, Value (US$ Mn), 2018 - 2031
      • 5.5.1.22. Russia Systemic Scleroderma Treatment Market by Treatment Type, Value (US$ Mn), 2018 - 2031
      • 5.5.1.23. Russia Systemic Scleroderma Treatment Market by Route of Administration, Value (US$ Mn), 2018 - 2031
      • 5.5.1.24. Russia Systemic Scleroderma Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
      • 5.5.1.25. Rest of Europe Systemic Scleroderma Treatment Market by Target Organ, Value (US$ Mn), 2018 - 2031
      • 5.5.1.26. Rest of Europe Systemic Scleroderma Treatment Market by Treatment Type, Value (US$ Mn), 2018 - 2031
      • 5.5.1.27. Rest of Europe Systemic Scleroderma Treatment Market by Route of Administration, Value (US$ Mn), 2018 - 2031
      • 5.5.1.28. Rest of Europe Systemic Scleroderma Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
    • 5.5.2. BPS Analysis/Market Attractiveness Analysis

6. Asia Pacific Systemic Scleroderma Treatment Market Outlook, 2018 - 2031

  • 6.1. Asia Pacific Systemic Scleroderma Treatment Market Outlook, by Target Organ, Value (US$ Mn), 2018 - 2031
    • 6.1.1. Key Highlights
      • 6.1.1.1. Skin Fibrosis
      • 6.1.1.2. Musculoskeletal
      • 6.1.1.3. Digital Ulcers
      • 6.1.1.4. Pulmonary Arterial Hypertension
      • 6.1.1.5. Gastrointestinal
      • 6.1.1.6. Pulmonary Fibrosis
      • 6.1.1.7. Scleroderma Renal Crisis
  • 6.2. Asia Pacific Systemic Scleroderma Treatment Market Outlook, by Treatment Type, Value (US$ Mn), 2018 - 2031
    • 6.2.1. Key Highlights
      • 6.2.1.1. Drug Therapy
        • 6.2.1.1.1. Corticosteroids
        • 6.2.1.1.2. Immunosuppressants
        • 6.2.1.1.3. Nonsteroidal Anti-Inflammatory Drugs
        • 6.2.1.1.4. Calcium Channel Blockers
        • 6.2.1.1.5. Proton Pump Inhibitors
        • 6.2.1.1.6. TNF Inhibitors
        • 6.2.1.1.7. Endothelin Receptor Antagonists
        • 6.2.1.1.8. Phosphodiesterase Type 5 Inhibitors
        • 6.2.1.1.9. Angiotensin-Converting Enzyme
      • 6.2.1.2. Hematopoietic Stem Cell Transplantation (HSCT)
  • 6.3. Asia Pacific Systemic Scleroderma Treatment Market Outlook, by Route of Administration, Value (US$ Mn), 2018 - 2031
    • 6.3.1. Key Highlights
      • 6.3.1.1. Injectable Systemic Scleroderma Drugs
      • 6.3.1.2. Oral Systemic Scleroderma Drugs
      • 6.3.1.3. Topical Systemic Scleroderma Drugs
  • 6.4. Asia Pacific Systemic Scleroderma Treatment Market Outlook, by Distribution Channel, Value (US$ Mn), 2018 - 2031
    • 6.4.1. Key Highlights
      • 6.4.1.1. Hospital Pharmacies
      • 6.4.1.2. Speciality Clinics
      • 6.4.1.3. Retail Pharmacies
      • 6.4.1.4. Online Pharmacies
    • 6.4.2. BPS Analysis/Market Attractiveness Analysis
  • 6.5. Asia Pacific Systemic Scleroderma Treatment Market Outlook, by Country, Value (US$ Mn), 2018 - 2031
    • 6.5.1. Key Highlights
      • 6.5.1.1. China Systemic Scleroderma Treatment Market by Target Organ, Value (US$ Mn), 2018 - 2031
      • 6.5.1.2. China Systemic Scleroderma Treatment Market by Treatment Type, Value (US$ Mn), 2018 - 2031
      • 6.5.1.3. China Systemic Scleroderma Treatment Market by Route of Administration, Value (US$ Mn), 2018 - 2031
      • 6.5.1.4. China Systemic Scleroderma Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
      • 6.5.1.5. Japan Systemic Scleroderma Treatment Market by Target Organ, Value (US$ Mn), 2018 - 2031
      • 6.5.1.6. Japan Systemic Scleroderma Treatment Market by Treatment Type, Value (US$ Mn), 2018 - 2031
      • 6.5.1.7. Japan Systemic Scleroderma Treatment Market by Route of Administration, Value (US$ Mn), 2018 - 2031
      • 6.5.1.8. Japan Systemic Scleroderma Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
      • 6.5.1.9. South Korea Systemic Scleroderma Treatment Market by Target Organ, Value (US$ Mn), 2018 - 2031
      • 6.5.1.10. South Korea Systemic Scleroderma Treatment Market by Treatment Type, Value (US$ Mn), 2018 - 2031
      • 6.5.1.11. South Korea Systemic Scleroderma Treatment Market by Route of Administration, Value (US$ Mn), 2018 - 2031
      • 6.5.1.12. South Korea Systemic Scleroderma Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
      • 6.5.1.13. India Systemic Scleroderma Treatment Market by Target Organ, Value (US$ Mn), 2018 - 2031
      • 6.5.1.14. India Systemic Scleroderma Treatment Market by Treatment Type, Value (US$ Mn), 2018 - 2031
      • 6.5.1.15. India Systemic Scleroderma Treatment Market by Route of Administration, Value (US$ Mn), 2018 - 2031
      • 6.5.1.16. India Systemic Scleroderma Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
      • 6.5.1.17. Southeast Asia Systemic Scleroderma Treatment Market by Target Organ, Value (US$ Mn), 2018 - 2031
      • 6.5.1.18. Southeast Asia Systemic Scleroderma Treatment Market by Treatment Type, Value (US$ Mn), 2018 - 2031
      • 6.5.1.19. Southeast Asia Systemic Scleroderma Treatment Market by Route of Administration, Value (US$ Mn), 2018 - 2031
      • 6.5.1.20. Southeast Asia Systemic Scleroderma Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
      • 6.5.1.21. Rest of Asia Pacific Systemic Scleroderma Treatment Market by Target Organ, Value (US$ Mn), 2018 - 2031
      • 6.5.1.22. Rest of Asia Pacific Systemic Scleroderma Treatment Market by Treatment Type, Value (US$ Mn), 2018 - 2031
      • 6.5.1.23. Rest of Asia Pacific Systemic Scleroderma Treatment Market by Route of Administration, Value (US$ Mn), 2018 - 2031
      • 6.5.1.24. Rest of Asia Pacific Systemic Scleroderma Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
    • 6.5.2. BPS Analysis/Market Attractiveness Analysis

7. Latin America Systemic Scleroderma Treatment Market Outlook, 2018 - 2031

  • 7.1. Latin America Systemic Scleroderma Treatment Market Outlook, by Target Organ, Value (US$ Mn), 2018 - 2031
    • 7.1.1. Key Highlights
      • 7.1.1.1. Skin Fibrosis
      • 7.1.1.2. Musculoskeletal
      • 7.1.1.3. Digital Ulcers
      • 7.1.1.4. Pulmonary Arterial Hypertension
      • 7.1.1.5. Gastrointestinal
      • 7.1.1.6. Pulmonary Fibrosis
      • 7.1.1.7. Scleroderma Renal Crisis
  • 7.2. Latin America Systemic Scleroderma Treatment Market Outlook, by Treatment Type, Value (US$ Mn), 2018 - 2031
    • 7.2.1. Key Highlights
      • 7.2.1.1. Drug Therapy
        • 7.2.1.1.1. Corticosteroids
        • 7.2.1.1.2. Immunosuppressants
        • 7.2.1.1.3. Nonsteroidal Anti-Inflammatory Drugs
        • 7.2.1.1.4. Calcium Channel Blockers
        • 7.2.1.1.5. Proton Pump Inhibitors
        • 7.2.1.1.6. TNF Inhibitors
        • 7.2.1.1.7. Endothelin Receptor Antagonists
        • 7.2.1.1.8. Phosphodiesterase Type 5 Inhibitors
        • 7.2.1.1.9. Angiotensin-Converting Enzyme
      • 7.2.1.2. Hematopoietic Stem Cell Transplantation (HSCT)
  • 7.3. Latin America Systemic Scleroderma Treatment Market Outlook, by Route of Administration, Value (US$ Mn), 2018 - 2031
    • 7.3.1. Key Highlights
      • 7.3.1.1. Injectable Systemic Scleroderma Drugs
      • 7.3.1.2. Oral Systemic Scleroderma Drugs
      • 7.3.1.3. Topical Systemic Scleroderma Drugs
  • 7.4. Latin America Systemic Scleroderma Treatment Market Outlook, by Distribution Channel, Value (US$ Mn), 2018 - 2031
    • 7.4.1. Key Highlights
      • 7.4.1.1. Hospital Pharmacies
      • 7.4.1.2. Speciality Clinics
      • 7.4.1.3. Retail Pharmacies
      • 7.4.1.4. Online Pharmacies
    • 7.4.2. BPS Analysis/Market Attractiveness Analysis
  • 7.5. Latin America Systemic Scleroderma Treatment Market Outlook, by Country, Value (US$ Mn), 2018 - 2031
    • 7.5.1. Key Highlights
      • 7.5.1.1. Brazil Systemic Scleroderma Treatment Market by Target Organ, Value (US$ Mn), 2018 - 2031
      • 7.5.1.2. Brazil Systemic Scleroderma Treatment Market by Treatment Type, Value (US$ Mn), 2018 - 2031
      • 7.5.1.3. Brazil Systemic Scleroderma Treatment Market by Route of Administration, Value (US$ Mn), 2018 - 2031
      • 7.5.1.4. Brazil Systemic Scleroderma Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
      • 7.5.1.5. Mexico Systemic Scleroderma Treatment Market by Target Organ, Value (US$ Mn), 2018 - 2031
      • 7.5.1.6. Mexico Systemic Scleroderma Treatment Market by Treatment Type, Value (US$ Mn), 2018 - 2031
      • 7.5.1.7. Mexico Systemic Scleroderma Treatment Market by Route of Administration, Value (US$ Mn), 2018 - 2031
      • 7.5.1.8. Mexico Systemic Scleroderma Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
      • 7.5.1.9. Argentina Systemic Scleroderma Treatment Market by Target Organ, Value (US$ Mn), 2018 - 2031
      • 7.5.1.10. Argentina Systemic Scleroderma Treatment Market by Treatment Type, Value (US$ Mn), 2018 - 2031
      • 7.5.1.11. Argentina Systemic Scleroderma Treatment Market by Route of Administration, Value (US$ Mn), 2018 - 2031
      • 7.5.1.12. Argentina Systemic Scleroderma Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
      • 7.5.1.13. Rest of Latin America Systemic Scleroderma Treatment Market by Target Organ, Value (US$ Mn), 2018 - 2031
      • 7.5.1.14. Rest of Latin America Systemic Scleroderma Treatment Market by Treatment Type, Value (US$ Mn), 2018 - 2031
      • 7.5.1.15. Rest of Latin America Systemic Scleroderma Treatment Market by Route of Administration, Value (US$ Mn), 2018 - 2031
      • 7.5.1.16. Rest of Latin America Systemic Scleroderma Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
    • 7.5.2. BPS Analysis/Market Attractiveness Analysis

8. Middle East & Africa Systemic Scleroderma Treatment Market Outlook, 2018 - 2031

  • 8.1. Middle East & Africa Systemic Scleroderma Treatment Market Outlook, by Target Organ, Value (US$ Mn), 2018 - 2031
    • 8.1.1. Key Highlights
      • 8.1.1.1. Skin Fibrosis
      • 8.1.1.2. Musculoskeletal
      • 8.1.1.3. Digital Ulcers
      • 8.1.1.4. Pulmonary Arterial Hypertension
      • 8.1.1.5. Gastrointestinal
      • 8.1.1.6. Pulmonary Fibrosis
      • 8.1.1.7. Scleroderma Renal Crisis
  • 8.2. Middle East & Africa Systemic Scleroderma Treatment Market Outlook, by Treatment Type, Value (US$ Mn), 2018 - 2031
    • 8.2.1. Key Highlights
      • 8.2.1.1. Drug Therapy
        • 8.2.1.1.1. Corticosteroids
        • 8.2.1.1.2. Immunosuppressants
        • 8.2.1.1.3. Nonsteroidal Anti-Inflammatory Drugs
        • 8.2.1.1.4. Calcium Channel Blockers
        • 8.2.1.1.5. Proton Pump Inhibitors
        • 8.2.1.1.6. TNF Inhibitors
        • 8.2.1.1.7. Endothelin Receptor Antagonists
        • 8.2.1.1.8. Phosphodiesterase Type 5 Inhibitors
        • 8.2.1.1.9. Angiotensin-Converting Enzyme
      • 8.2.1.2. Hematopoietic Stem Cell Transplantation (HSCT)
  • 8.3. Middle East & Africa Systemic Scleroderma Treatment Market Outlook, by Route of Administration, Value (US$ Mn), 2018 - 2031
    • 8.3.1. Key Highlights
      • 8.3.1.1. Injectable Systemic Scleroderma Drugs
      • 8.3.1.2. Oral Systemic Scleroderma Drugs
      • 8.3.1.3. Topical Systemic Scleroderma Drugs
  • 8.4. Middle East & Africa Systemic Scleroderma Treatment Market Outlook, by Distribution Channel, Value (US$ Mn), 2018 - 2031
    • 8.4.1. Key Highlights
      • 8.4.1.1. Hospital Pharmacies
      • 8.4.1.2. Speciality Clinics
      • 8.4.1.3. Retail Pharmacies
      • 8.4.1.4. Online Pharmacies
    • 8.4.2. BPS Analysis/Market Attractiveness Analysis
  • 8.5. Middle East & Africa Systemic Scleroderma Treatment Market Outlook, by Country, Value (US$ Mn), 2018 - 2031
    • 8.5.1. Key Highlights
      • 8.5.1.1. GCC Systemic Scleroderma Treatment Market by Target Organ, Value (US$ Mn), 2018 - 2031
      • 8.5.1.2. GCC Systemic Scleroderma Treatment Market by Treatment Type, Value (US$ Mn), 2018 - 2031
      • 8.5.1.3. GCC Systemic Scleroderma Treatment Market by Route of Administration, Value (US$ Mn), 2018 - 2031
      • 8.5.1.4. GCC Systemic Scleroderma Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
      • 8.5.1.5. South Africa Systemic Scleroderma Treatment Market by Target Organ, Value (US$ Mn), 2018 - 2031
      • 8.5.1.6. South Africa Systemic Scleroderma Treatment Market by Treatment Type, Value (US$ Mn), 2018 - 2031
      • 8.5.1.7. South Africa Systemic Scleroderma Treatment Market by Route of Administration, Value (US$ Mn), 2018 - 2031
      • 8.5.1.8. South Africa Systemic Scleroderma Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
      • 8.5.1.9. Egypt Systemic Scleroderma Treatment Market by Target Organ, Value (US$ Mn), 2018 - 2031
      • 8.5.1.10. Egypt Systemic Scleroderma Treatment Market by Treatment Type, Value (US$ Mn), 2018 - 2031
      • 8.5.1.11. Egypt Systemic Scleroderma Treatment Market by Route of Administration, Value (US$ Mn), 2018 - 2031
      • 8.5.1.12. Egypt Systemic Scleroderma Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
      • 8.5.1.13. Nigeria Systemic Scleroderma Treatment Market by Target Organ, Value (US$ Mn), 2018 - 2031
      • 8.5.1.14. Nigeria Systemic Scleroderma Treatment Market by Treatment Type, Value (US$ Mn), 2018 - 2031
      • 8.5.1.15. Nigeria Systemic Scleroderma Treatment Market by Route of Administration, Value (US$ Mn), 2018 - 2031
      • 8.5.1.16. Nigeria Systemic Scleroderma Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
      • 8.5.1.17. Rest of Middle East & Africa Systemic Scleroderma Treatment Market by Target Organ, Value (US$ Mn), 2018 - 2031
      • 8.5.1.18. Rest of Middle East & Africa Systemic Scleroderma Treatment Market by Treatment Type, Value (US$ Mn), 2018 - 2031
      • 8.5.1.19. Rest of Middle East & Africa Systemic Scleroderma Treatment Market by Route of Administration, Value (US$ Mn), 2018 - 2031
      • 8.5.1.20. Rest of Middle East & Africa Systemic Scleroderma Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
    • 8.5.2. BPS Analysis/Market Attractiveness Analysis

9. Competitive Landscape

  • 9.1. Target Organ vs Route of Administration Heatmap
  • 9.2. Manufacturer vs Indication Heatmap
  • 9.3. Company Market Share Analysis, 2023
  • 9.4. Competitive Dashboard
  • 9.5. Company Profiles
    • 9.5.1. Pfizer Inc.
      • 9.5.1.1. Company Overview
      • 9.5.1.2. Product Portfolio
      • 9.5.1.3. Financial Overview
      • 9.5.1.4. Business Strategies and Development
    • 9.5.2. Novartis AG
      • 9.5.2.1. Company Overview
      • 9.5.2.2. Product Portfolio
      • 9.5.2.3. Financial Overview
      • 9.5.2.4. Business Strategies and Development
    • 9.5.3. GlaxoSmithKline plc.
      • 9.5.3.1. Company Overview
      • 9.5.3.2. Product Portfolio
      • 9.5.3.3. Financial Overview
      • 9.5.3.4. Business Strategies and Development
    • 9.5.4. Sanofi SA
      • 9.5.4.1. Company Overview
      • 9.5.4.2. Product Portfolio
      • 9.5.4.3. Financial Overview
      • 9.5.4.4. Business Strategies and Development
    • 9.5.5. Lupin Ltd
      • 9.5.5.1. Company Overview
      • 9.5.5.2. Product Portfolio
      • 9.5.5.3. Financial Overview
      • 9.5.5.4. Business Strategies and Development
    • 9.5.6. Cipla Ltd
      • 9.5.6.1. Company Overview
      • 9.5.6.2. Product Portfolio
      • 9.5.6.3. Financial Overview
      • 9.5.6.4. Business Strategies and Development
    • 9.5.7. Johnson & Johnson Services Inc.
      • 9.5.7.1. Company Overview
      • 9.5.7.2. Product Portfolio
      • 9.5.7.3. Financial Overview
      • 9.5.7.4. Business Strategies and Development
    • 9.5.8. Bayer Healthcare LLC
      • 9.5.8.1. Company Overview
      • 9.5.8.2. Product Portfolio
      • 9.5.8.3. Financial Overview
      • 9.5.8.4. Business Strategies and Development
    • 9.5.9. F. Hoffmann-La Roche Ltd
      • 9.5.9.1. Company Overview
      • 9.5.9.2. Product Portfolio
      • 9.5.9.3. Financial Overview
      • 9.5.9.4. Business Strategies and Development
    • 9.5.10. Amgen Inc
      • 9.5.10.1. Company Overview
      • 9.5.10.2. Product Portfolio
      • 9.5.10.3. Financial Overview
      • 9.5.10.4. Business Strategies and Development
    • 9.5.11. Zydus Lifesciences Ltd
      • 9.5.11.1. Company Overview
      • 9.5.11.2. Product Portfolio
      • 9.5.11.3. Financial Overview
      • 9.5.11.4. Business Strategies and Development
    • 9.5.12. Casper Pharma
      • 9.5.12.1. Company Overview
      • 9.5.12.2. Product Portfolio
      • 9.5.12.3. Financial Overview
      • 9.5.12.4. Business Strategies and Development
    • 9.5.13. Boehringer Ingelheim Pharmaceuticals, Inc.
      • 9.5.13.1. Company Overview
      • 9.5.13.2. Product Portfolio
      • 9.5.13.3. Financial Overview
      • 9.5.13.4. Business Strategies and Development
    • 9.5.14. Organon LLC
      • 9.5.14.1. Company Overview
      • 9.5.14.2. Product Portfolio
      • 9.5.14.3. Financial Overview
      • 9.5.14.4. Business Strategies and Development
    • 9.5.15. Accord Healthcare Inc.
      • 9.5.15.1. Company Overview
      • 9.5.15.2. Product Portfolio
      • 9.5.15.3. Financial Overview
      • 9.5.15.4. Business Strategies and Development

10. Appendix

  • 10.1. Research Methodology
  • 10.2. Report Assumptions
  • 10.3. Acronyms and Abbreviations
샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제